3.00
-0.99%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shandong Boan Biotechnology Co
Its shares trade on HKEX under the ticker 6955.HK. It has been listed since 30 December 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥784.8m and net income of CN¥7.1m. At that date it held total assets of CN¥4.13bn and shareholders' equity of CN¥2.74bn.
Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Dec 2022
- Employees
- 745
- Website
- boan-bio.com ↗
Leadership
Pay as last reported
- Ms. Hua JiangExecutive Chairlady of the Board, Chief Executive OfficerCN¥7.4m
- Mr. Shenghan WangChief Financial Officer
- Dr. Changlin DouPresident - Research and Development, Chief Operating Officer, Executive DirectorCN¥7.7m
- Mr. Jun LuSenior Vice President, Head - Biotechnology Engineering Center and Quality Department
- Mr. Guangming ChiVice President - Business Operations Center
- Mr. Deyong SongHead - Biologics Discovery Department
- Ms. Siu Kuen LaiCompany Secretary
- Ms. Li LiNon-Executive DirectorCN¥1.6m
- Mr. Yuanchong LiuNon-Executive DirectorCN¥1.8m
- Mr. Jixiong DaiNon-Executive Independent DirectorCN¥75,000
- Mr. Luwen ShiNon-Executive Independent DirectorCN¥75,000
- Dr. Jialin YuNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shandong Boan Biotechnology employs 745 full-time staff members for its operations.
- The company utilizes three main technology platforms for therapeutic antibody development.
- Shandong Boan Biotechnology focuses on oncology and metabolism therapeutic areas.
Weaknesses
- The company is headquartered in Yantai, Shandong, which limits local talent pools.
- Shandong Boan Biotechnology went public on 30 December 2022, indicating recent market entry.
- The firm operates mainly in the domestic Chinese market with limited global reach.
Opportunities
- Shandong Boan Biotechnology can expand its therapeutic antibody commercialization in overseas markets.
- The bispecific T-cell Engager platform offers new avenues for autoimmunology treatments.
- Shandong Boan Biotechnology can leverage its ADC technology platform for new drug candidates.
Threats
- Shandong Boan Biotechnology faces intense competition in the domestic Chinese biotechnology sector.
- Regulatory changes in China could impact the commercialization of therapeutic antibodies.
- Shandong Boan Biotechnology may struggle with manufacturing scalability for its antibody platforms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.